Internal medicine (Tokyo, Japan) · 2020
Dasatinib-induced Nonspecific Interstitial Pneumonia That Developed 7 Years after the Initiation of Dasatinib.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Takekoshi Daisuke, Matsui Yuma, Akutsu Takuya, Nishioka Ayako, Kiritani Ayu, Okuda Keitaro, Watanabe Junko, Miyagawa Hanae, Utsumi Hirohumi, Hashimoto Mitsuo, Wakui Hiroshi, Minagawa Shunsuke, Hara Hiromichi, Numata Takanori, Noda Yuki, Makishima Rei, Ikegami Masahiro, Kawabata Yoshinori, Araya Jun, Kuwano Kazuyoshi
Аннотация
We report the case of a 56-year-old man with chronic myeloid leukemia (CML) who developed dasatinib-induced interstitial lung disease (ILD) 7 years after starting dasatinib, a BCR-ABL1 inhibitor. The patient presented with dyspnea. Chest imaging showed diffuse ground-glass opacities. A surgical lung biopsy showed cellular non-specific interstitial pneumonia (NSIP). Corticosteroid treatment ameliorated his condition. Bosutinib, another BCR-ABL1 inhibitor, was successfully re-instituted. The present case and relevant literature suggest that dasatinib-induced ILD can present as NSIP after an extended period, responds to corticosteroids, and is amenable to re-challenge at a lower-dose or with alternative BCR-ABL1 inhibitors.